Extending Ischemic Stroke Golden Hour to 72 Hours, Meridigen Gets USFDA Green Light to New Drug Clinical Trial.

Meridigen New Neonatal Stem Cell Drug Received TFDA Approval for Clinical Trial

Taiwan's high-tech guru John Hsuan (宣明智) aims for significant growth in mainland China's market in order to make the biotech industry the next pride of Taiwan. The honorary vice chairman...

The development of mesenchymal stem cell research by Meridigen Biotech Co. Ltd. had good news. Yogi Hsuan, the general manager of Meridigen, indicated that the new biomarker EphA2 used to...

The 3rd “Cross-Straits Forum on Creative Industries Cooperation” was held in Chongqing City of Mainland China in October 25, 2015. Two main fields including cultural and creative and biomedical issues...